Needham & Company Starts Auris Medical Holding AG (EARS) at Buy

Needham & Company initiates coverage on Auris Medical Holding AG (NASDAQ: EARS) with a Buy rating and a price target of $11.00.

Analyst Elliot Wilbur comments, "We are initiating coverage of Auris Medical Holding AG (EARS), an emerging specialty pharma leader in otology. Auris has a novel drug delivery approach focused on proprietary gel formulations for local treatment in the inner ear via intratympanic injections. The company has two advanced product candidates: AM-101 for acute tinnitus currently under phase 3 evaluation with results expected in early 2016, and AM-111 for acute hearing loss expected to begin phase 3 trials in early 2015. Given our view that both AM-101 and AM-111 have the potential to be first-in-class products in their respective indications, we believe Auris has the potential to emerge as a leader in the otology field."

NOTE: Needham & Company was a co-manager in the recent IPO.

For an analyst ratings summary and ratings history on Auris Medical Holding AG click here. For more ratings news on Auris Medical Holding AG click here.

Shares of Auris Medical Holding AG closed at $6.09 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• UBS Downgrades Hino Motors Ltd. (7205:JP) (HINOY) to Neutral
• HSBC Downgrades Anglo American Platinum Limited (AMS:SJ) (ANGPY) to Reduce